Paris, 28 November 2012: The 2012 Pasteur-Weizmann/Servier Prize is awarded to Professor Caroline Dive for her remarkable advances in cancer research in the development of circulating biomarkers.
The 2012 Pasteur-Weizmann/Servier Prize is one of the world’s leading scientific awards, carrying prize money of €150,000. It is awarded every three years to a researcher or research team in recognition of a major contribution to a biomedical discovery leading to a therapeutic application. The Prize aims to promote and encourage fundamental research, in particular the transition from laboratory research to medical therapy.
Professor Caroline Dive is Professor of Pharmacology at the University of Manchester. She heads the Clinical and Experimental Pharmacology Group, focusing on translational oncology, at the University’s Paterson Institute for Cancer Research which is part of the Manchester Cancer Research Centre (MCRC).
Professor Dive and her team are working on non-invasive procedures to aid in diagnosis and predicting responses to treatment: circulating biomarkers and the identification of circulating tumoural cells. Professor Dive is the author of 249 publications in leading international scientific journals.
“I am truly honoured to receive the 2012 Pasteur-Weizmann/Servier Prize. This is a major international award that has been made in the past to researchers for whom I have the highest admiration,” said Professor Dive at the award ceremony: “The equipment required to analyse circulating tumour cells and understand their biology calls for huge investment. The Prize will be a very welcome boost to our funds.”
The Pasteur-Weizmann/Servier International Prize was awarded for research in the « development of non-invasive procedures (imaging and markers) for the diagnosis and management of cancer » 28 november 2012 in Paris.
The Pasteur-Weizmann/Servier International Prize for biomedical research with a therapeutic aim is awarded every three years to a top-level researcher, scientist or physician, internationally renowned for their major contribution to a biomedical discovery leading to a therapeutic application. The prize concerns themes that are of joint interest to the Pasteur-Weizmann Committee and the Servier Institute with the aim of promoting and encouraging fundamental research, in particular the transition from laboratory research to medical therapy.